IP Library Granted Patent US 9,650,359
Granted Patent B2
US 9,650,359 · App. 15/158,432 · Granted May 16, 2017

Modulators of resistant androgen receptor

Inventors: Minna D. Balbas (San Francisco, CA); Michael J. Evans (New York, NY); Charles L. Sawyers (New York, NY); Yang Shen (Chicago, IL); David Hosfield (Chicago, IL); Geoffrey L. Greene (Chicago, IL)
Assignee: Memorial Sloan-Kettering Cancer Center
C07D401/04C07D233/86C07D235/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,650,359
App. No.
15/158,432
Granted
May 16, 2017
Kind
B2
Abstract

The present invention provides compounds useful as modulators, agonists or antagonists of androgen receptor (AR), compositions thereof, and methods of making and using the same.

Claims (14)

1. A method of treating a cancer comprising administering to a patient in need thereof a compound represented by structural formula IV:

or a pharmaceutically acceptable salt thereof, wherein:

X is CH or N;

each R b is independently substituted or unsubstituted C 1-6 aliphatic; and

n is 0 to 4.

2. The method of claim 1 , wherein the cancer is a castration-resistant prostate cancer.

3. The method of claim 2 , wherein the castration-resistant prostate cancer bears one or more mutations in the androgen receptor.

4. The method of claim 3 , wherein the one or more mutations in the androgen receptor comprises a mutation of Phe876.

5. The method of claim 4 , wherein the mutation is Phe876 to Leu, Ile, Val, Ser, Cys, or Tyr.

6. The method of claim 4 , wherein the mutations further comprise one or more mutations to residues selected from the group consisting of E566, E589, E669, C687, A700, N772, H777, C785, F877, and K911.

7. The method of claim 2 , wherein the castration-resistant prostate cancer is resistant to Enzalutamide.

8. The method of claim 1 , wherein the compound is:

9. The method of claim 8 , wherein the compound is represented by the following structural formula:

10. The method of claim 8 , wherein the compound is represented by the following structural formula:

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2017
From: BALBAS, MINNA D.; EVANS, MICHAEL J.; SAWYERS, CHARLES L.; SHEN, YANG; HOSFIELD, DAVID; GREENE, GEOFFREY L.
To: MEMORIAL SLOAN-KETTERING CANCER CENTER
Reel/Frame 041770/0444 →
CONFIRMATORY LICENSE Recorded Sep 15, 2016
From: SLOAN-KETTERING INST CAN RESEARCH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 040041/0276 →
Continuity (3)
Division 14438584
Provisional Application 61719117 · Oct 26, 2012
Related Publication 20160257666A1 · Sep 8, 2016